Document Detail


Everolimus and giant-cell astrocytomas in tuberous sclerosis.
MedLine Citation:
PMID:  21306252     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To the Editor: Krueger et al. (Nov. 4 issue)(1) report on a striking effect of everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), on subependymal giant-cell astrocytomas, which are benign tumors composed of large ganglionic astrocytes. These tumors show strong expression of CD98 (the heavy chain of 4F2 cell-surface antigen and fusion regulatory protein 1) and a system L-type amino acid transporter (LAT-1) that induces multinucleated giant-cell formation and is essential for the maintenance of cell volume. Inhibition of the mTOR signaling pathway has been shown to decrease the activity of the system LAT-1,(2) which we speculate . . .
Authors:
Ji Jia; Lize Xiong; Shaoyang Chen
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  364     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  576-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety of Recombinant Activated Factor VII in Randomized Clinical Trials.
Next Document:  Everolimus and giant-cell astrocytomas in tuberous sclerosis.